Work

Novel HIV PR inhibitors with C4-substituted bis-THF and bis-fluoro-benzyl target the two active site mutations of highly drug resistant mutant PRS17

Year: 2021

Type: article

Source: Biochemical and Biophysical Research Communications

DOI: 10.1016/j.bbrc.2021.05.094

Authors: Johnson Agniswamy, Daniel W. Kneller, Arun K. Ghosh, Irene T. Weber

Institutions: Georgia State University, Purdue University West Lafayette

Language: English

Topic: HIV/AIDS drug development and treatment

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: U.S. Department of Energy, National Institutes of Health, Office of Science, National Institute of Allergy and Infectious Diseases, Basic Energy Sciences, Argonne National Laboratory

Awards: G1756342139, Inhibition of Resistant Variants of HIV Protease, Design & Synthesis of Nonpeptide Protease Inhibitors, G9000026535, Design & Synthesis of Nonpeptide Protease Inhibitors

OpenAlex ID: W3167616167

FWCI: 0.316

Cites: 41

Cited by: 7

Related to: 10